Analyst
H.C. Wainwright
Equibles does not estimate personal net worth.
Arthur He is recorded as Analyst at H.C. Wainwright. Arthur He has spoken on 5 earnings calls and 4 other investor events across 7 companies, most recently for Vera Therapeutics, Inc. on October 22, 2026. Those appearances were for Nektar Therapeutics (NKTR), BioAtla, Inc. (BCAB), Vera Therapeutics, Inc. (VERA), ImageneBio, Inc. (IMA), Satellos Bioscience Inc. (MSLE) and 2 other companies. The companies whose calls Arthur He spoke on are classified in the Healthcare sector.
“So I just had two quick questions, one for Mendren and the other for Dr. Barrett. So, Marshall, I know for these current data set, you only include about one-fourth of patients for the final readout.”
“And for Dr. Unger, given the activity continued for the off-treatment period, how should we think about the continued dosing in the real world use of this drug?”
“We have a conversation with Dr. Christine Yarema, CEO of ImagineBio. Christine, thanks for coming down.”
“Just one quick question on the T99C. Do you guys have the data for the three-month measurements for the T99C? And also, what's your thoughts on using this endpoint for a regulatory, like for the approval endpoint when you're talking to the agency for the non-abitory patient.”
“I just had a quick question for the management and a couple of questions for the physicians. So maybe for the physician first. So when we look at this data, how should we think about the RESPEX efficacy in the alopecia patient with soft score less than 50?”
H.C. Wainwright
Analyst
Source not stated
NKTR
Biotechnology · Healthcare
BCAB
Biotechnology · Healthcare
IMA
Biotechnology · Healthcare
PSNL
Diagnostics & Research · Healthcare
